Vasculitis, Takayasu Arteritis, and Inflammatory Arteriopathies

50.1Control inflammation before routine repair

The first vascular decision in large-vessel vasculitis is not whether an artery is narrowed, occluded, or dilated; it is whether the current risk is active inflammation, fixed damage, or an immediately threatened vascular territory. EULAR large-vessel vasculitis management guidance and the ACR/Vasculitis Foundation guideline for giant cell arteritis and Takayasu arteritis support assessing disease activity and controlling active inflammation before routine vascular repair, rather than planning elective intervention from anatomy alone ACR 2021 · EULAR 2018. This is the central difference between an atherosclerotic renal-artery stenosis and a renal-artery lesion in Takayasu arteritis, or between degenerative aortic disease and an aortic abnormality in giant cell arteritis.

For the vascular surgeon, the practical question is: what harm is this lesion causing today? In giant cell arteritis, the answer may involve cranial or ocular danger, limb ischemia, aortic inflammation, aneurysmal change, or branch-vessel stenosis. In Takayasu arteritis, the presentation may be pulse deficit, arm claudication, renal-artery involvement, cerebrovascular symptoms, coarctation-like aortic narrowing, aneurysm, or malperfusion. These presentations are not interchangeable, but they share a sequence: identify active disease, define the vascular consequence, and decide whether the consequence can safely wait for inflammatory control. The ACR/VF guidance supports the general preference for intervention in Takayasu arteritis during controlled disease while preserving urgent exceptions when vascular threat makes delay unsafe ACR 2021.

Disease activity cannot be reduced to one inflammatory-marker value or one imaging phrase. Symptoms, pulse examination, blood-pressure differentials, inflammatory-marker trend, prior imaging, current treatment, and lesion behavior over time all contribute. A patient with constitutional symptoms, rising markers, new vessel-wall signal, and evolving pain is different from a patient with stable claudication from a long-standing occlusion after years of quiescent disease. The same duplex velocity or CTA stenosis may therefore represent active disease with remodelling potential, chronic fixed damage, or both. EULAR imaging recommendations and contemporary imaging reviews emphasise that inflammatory activity and accumulated vascular damage are related but not identical EULAR recommendations use 2023 · LVV 2024.

This distinction defines how the vascular and rheumatology roles meet. Rheumatology leads confirmation of the inflammatory syndrome, systemic treatment, relapse assessment, and longitudinal control of disease activity. Vascular surgery defines hemodynamic consequence, limb or organ threat, aneurysm danger, procedural feasibility, and the expected durability problem. Repair performed without understanding the inflammatory state risks treating a moving target. Medical treatment continued without vascular reassessment can miss renal, cerebral, mesenteric, limb, or aortic danger that is no longer solved by inflammation control alone.

The stable-patient sequence should therefore be deliberate. Establish the likely phenotype; confirm the diagnosis with imaging or histology when appropriate; decide whether the dominant issue is inflammation, damage, or both; treat active disease; then ask whether a residual stenosis, occlusion, aneurysm, or malperfusion syndrome still requires repair. Takayasu renal-artery disease illustrates the point: systematic review data on Takayasu-induced renal arteritis support the clinical importance of combining medical control with selected revascularization when hypertension, renal risk, or malperfusion persists, but the timing still turns on inflammatory state and urgency Advancements medical surgical 2020.

Emergency presentations use a different rule. Critical limb ischemia, threatened renal or mesenteric perfusion, escalating cerebral malperfusion, aneurysm danger, rupture concern, or another time-sensitive vascular complication can force intervention before ideal inflammatory control has been achieved. That is not a rejection of inflammation-first care; it is recognition that the cost of waiting has become greater than the biological penalty of intervening during active disease. When this occurs, the operative note and follow-up plan should state the presumed inflammatory state, the immediate vascular threat, and the reason earlier repair was justified ACR 2021 · Advancements medical surgical 2020.

Before elective repair, the team should record a usable baseline: recent symptoms, vascular examination, inflammatory-marker trend, current anti-inflammatory treatment, imaging evidence of wall disease, luminal damage, aneurysm status, prior interventions, and the specific vascular consequence being treated. That baseline prevents later confusion when postoperative pain, persistent wall signal, a new duplex abnormality, or restenosis raises the question of relapse versus repair failure. It also gives the patient a coherent explanation: medical treatment is not a delay in care when active inflammation is the dominant problem; it is part of making any later reconstruction safer and more durable. Systematic reviews of Takayasu medical therapy, including conventional disease-modifying therapy and tocilizumab literature, support the broader principle that medical control is a central part of care, although detailed drug selection is outside this chapter’s vascular scope Systematic review meta-analysis 2023 · Disease-modifying anti-rheumatic drugs 2021.

50.2Imaging asks the clinical question

Imaging in large-vessel vasculitis should begin with a sentence, not a modality: confirm suspected disease, map extent, assess activity, define fixed damage, follow an aneurysm, evaluate perfusion consequence, or plan a procedure. EULAR’s 2023 imaging recommendations frame ultrasound, CTA, MRA, and FDG-PET as complementary tests whose value depends on vessel territory, urgency, expertise, and the distinction between inflammation and structural damage EULAR recommendations use 2023. The systematic review supporting that update and contemporary imaging synthesis reach the same practical conclusion: the best test is the one that answers the management question at hand LVV 2023 · LVV 2024.

Clinical features and inflammatory markers are necessary, but they are not enough to make every diagnosis or to classify every vascular abnormality. A systematic review of symptoms, signs, and laboratory tests in giant cell arteritis found that these bedside and laboratory elements have limited diagnostic accuracy when used alone, which supports confirmatory imaging or biopsy when clinically appropriate Diagnostic Accuracy Symptoms 2020. At the same time, the vascular team must not let diagnostic perfection delay treatment in high-risk syndromes. Diagnostic delay in giant cell arteritis is clinically important, particularly when visual symptoms or other organ-threatening features are present, so treatment and confirmation often need to proceed in parallel ACR 2021 · EULAR 2018 · Diagnostic delay giant 2017.

Ultrasound is most useful when the suspected vessels are accessible and the operator has disease-specific expertise. It can support assessment of temporal and selected extracranial arteries, detect wall abnormality, and follow hemodynamic consequences in accessible beds. Its limitation is not merely technical; it may answer the wrong question when the clinical concern is thoracic aortic involvement, deep branch-vessel disease, aneurysm morphology, or operative planning. CTA is often the acute vascular study when rapid mapping of lumen, occlusion, thrombus, calcification, aneurysm, branch involvement, access, and landing zones is required. CTA is less suited to making inflammatory activity the sole management variable, because luminal narrowing and wall abnormality do not automatically distinguish active relapse from chronic damage EULAR recommendations use 2023 · LVV 2024.

MRA is valuable when repeated cross-sectional imaging is expected, when wall and lumen need to be evaluated together, or when avoidance of iodinated contrast is important. It can define aortic and branch-vessel involvement and support longitudinal comparison, provided local protocols are consistent enough for follow-up. Practical constraints include availability, acquisition time, patient tolerance, implanted devices, urgency, and protocol quality. FDG-PET is most useful when the question is metabolic inflammatory activity or whole-body distribution of large-vessel involvement, especially when symptoms, inflammatory markers, and conventional imaging do not align. It is not a substitute for high-resolution luminal planning when the next decision is bypass target, endovascular landing zone, aneurysm morphology, or access strategy EULAR recommendations use 2023 · LVV 2023 · LVV 2024.

The most common interpretive error is to treat every abnormal artery as active vasculitis. Fixed stenosis, chronic occlusion, post-treatment wall change, aneurysm, and collateralised malperfusion may persist after inflammation has improved. Conversely, active wall inflammation may precede a dramatic luminal lesion. This is why follow-up imaging must be read alongside symptoms, examination, inflammatory markers, treatment status, and prior imaging. EULAR imaging guidance supports imaging as part of clinical assessment rather than as an isolated verdict, and imaging reviews emphasise the need to separate inflammatory activity from accumulated vascular damage EULAR recommendations use 2023 · LVV 2024.

A useful imaging report should become a management statement. It should say which arteries are involved; whether the abnormality is wall-predominant, lumen-predominant, aneurysmal, or mixed; whether perfusion is threatened; whether interval change suggests activity, progression of damage, or treatment response; and whether there is a usable target, landing zone, or access route. Repeating a test that again documents a known stenosis is less valuable than choosing the modality that clarifies the next decision: activity, perfusion, aneurysm behavior, repair feasibility, or surveillance.

Longitudinal imaging should be comparable enough to detect change but flexible enough to respect the clinical question. A patient followed with MRA for aortic and branch-vessel disease may still need CTA when aneurysm repair is being planned. A patient diagnosed by ultrasound may need cross-sectional imaging when symptoms suggest deeper arterial involvement. A patient with persistent systemic symptoms and unclear anatomic progression may need PET-based assessment of inflammatory distribution. The aim is not to collect every modality; it is to choose the next study that resolves the next clinical decision.

When symptoms and imaging disagree, automatic repair is rarely the safest answer. New arm claudication with stable wall findings, persistent marker elevation without new vascular change, and aneurysm enlargement after apparent inflammatory control each raise different possibilities. The vascular surgeon should define the consequence—pressure loss, organ risk, tissue threat, aneurysm behavior, or access limitation—while the rheumatology team interprets systemic disease activity. Discordance should lead to a conditional plan: treat probable active disease, repeat or change imaging for a defined reason, or proceed to repair only when the vascular risk is clear.

50.3Repair timing must respect biology

Repair in Takayasu arteritis is a biological timing decision before it is an open-versus-endovascular decision. The lesion may be stenotic, occlusive, aneurysmal, or malperfusive, but the risk of restenosis, progression, or repair failure is shaped by whether the artery is actively inflamed. The ACR/VF guideline supports a general preference for vascular intervention when inflammation is controlled, while allowing earlier intervention when urgent ischemia, aneurysm threat, rupture concern, or malperfusion makes waiting unsafe ACR 2021. Systematic review data on Takayasu renal arteritis reinforce that revascularization is a selected vascular solution within an inflammatory disease, not a substitute for disease control Advancements medical surgical 2020.

The vascular surgeon usually enters care for one of four reasons. The first is danger: threatened vision, limb viability, renal perfusion, cerebral perfusion, mesenteric perfusion, aneurysm rupture concern, or severe malperfusion cannot be left to medical treatment alone while the patient deteriorates. The second is fixed damage: the inflammatory disease may be controlled, yet stenosis, occlusion, aneurysm, or pressure-gradient physiology continues to cause symptoms or organ risk. The third is diagnostic uncertainty: the lesion’s distribution, tempo, or imaging behavior may not fit the presumed inflammatory diagnosis. The fourth is planned reconstruction after medical stabilization, when the residual vascular problem has declared itself.

Before elective repair, three questions should be answered explicitly. Is there active inflammation that should be treated first? Is the vascular lesion causing a clinically important consequence despite medical control? Is the chosen anatomy suitable for durable repair in a patient whose disease may involve multiple territories over time? Angioplasty of an actively inflamed segment, stenting across a vessel that may remodel with treatment, bypass through inflamed inflow, or aneurysm repair without defining the extent of disease can fail for biological reasons even when the technical execution is sound. This is why elective Takayasu repair should be planned with the inflammatory state, lesion consequence, and future surveillance problem in the same discussion ACR 2021 · EULAR 2018.

Emergency repair follows a different calculus. When progressive malperfusion, threatened organ function, rupture concern, or another immediate vascular hazard is present, the goal is stabilization while acknowledging that the repair is being performed in unfavourable biology. The plan should minimise avoidable arterial trauma, preserve future access and landing options, and document the inflammatory context for later reassessment. The decision is not that inflammation has become irrelevant; it is that the harm of waiting now exceeds the harm of intervening during active or incompletely characterized disease ACR 2021.

Open and endovascular options should be chosen from lesion behavior, disease phase, and durability requirements rather than from habit. Endovascular treatment may be attractive for focal stenosis, high-risk patients, access-limited situations, or urgent stabilization, but it may be undermined by active wall inflammation, long-segment disease, recoil, restenosis, or inadequate landing zones. Open reconstruction may provide durable bypass around diseased segments, but it depends on safe inflow, safe outflow, tissue quality, and avoidance of inflamed or aneurysmal landing sites. Endarterectomy is not a generic solution for diffuse inflammatory disease; it belongs only where the anatomy and operative plane make sense. Imaging literature supports incorporating wall activity, luminal damage, and longitudinal behavior into this planning rather than relying on the angiogram alone EULAR recommendations use 2023 · LVV 2024.

Surveillance after repair must look for both vascular failure and inflammatory recurrence. Restenosis, graft or stent failure, aneurysm progression, new branch involvement, and persistent malperfusion are vascular outcomes. Recurrent systemic symptoms, renewed vessel-wall activity, and inflammatory relapse are disease outcomes. They overlap, but they are not identical. A repaired stenosis that narrows again may represent technical failure, progression of fixed damage, recurrent inflammation, or a combination; the response may be reintervention, treatment escalation, or both. EULAR imaging guidance supports follow-up imaging according to the clinical question, while imaging reviews caution against treating activity and damage as synonyms EULAR recommendations use 2023 · LVV 2024.

The same timing logic should not be casually extended to every inflammatory arteriopathy. It is strongest for large-vessel vasculitis, especially Takayasu arteritis and GCA-related large-vessel disease, where the accepted guidance and imaging literature directly address disease activity, vascular damage, and repair timing. Takayasu angiographic-type literature underscores the heterogeneity of arterial involvement, which is clinically useful for mapping disease extent, but it does not justify turning Takayasu timing principles into universal rules for medium-vessel or distal inflammatory syndromes Prevalence clinical severity 2025.

Before any planned intervention, the referral question should be rewritten in operative language. “Takayasu stenosis” is incomplete. “Controlled disease with persistent renal malperfusion and a focal treatable lesion” is actionable. “Active disease with escalating limb threat despite treatment” is actionable. “Uncertain diagnosis with atypical imaging and no threatened territory” is not an indication for reflex revascularization. The plan should state the intended benefit, why medical treatment alone is insufficient, what is known about current activity, the anatomic target, and how repair failure or relapse will be recognised.

Procedural sequencing should also protect future options. Large-vessel vasculitis can involve multiple territories over time, and a short-term fix that sacrifices a landing zone, injures an access vessel, or commits the patient to repeated reintervention may make later care harder. Conversely, excessive delay can allow avoidable renal, limb, cerebral, mesenteric, or aortic harm. The decision is therefore not “open versus endovascular” in the abstract; it is whether the selected repair solves the current vascular danger while preserving a credible path for future disease behavior.

50.4Keep inflammatory arteriopathy boundaries explicit

Large-vessel vasculitis guidance supports a practical framework for giant cell arteritis, Takayasu arteritis, and related aortic or branch-vessel complications; it should not be stretched into a full management scheme for every peripheral inflammatory arteriopathy. Medium-vessel vasculitis, thromboangiitis obliterans, Raynaud-spectrum disorders, and rare distal inflammatory syndromes may all reach the vascular clinic, but they do not automatically share the diagnostic tests, medical treatment, repair timing, or prognosis of GCA and Takayasu arteritis. EULAR large-vessel vasculitis guidance and ACR/VF GCA/Takayasu guidance should therefore be applied within their intended large-vessel context ACR 2021 · EULAR 2018.

The practical boundary is phenotype. Cranial symptoms, visual danger, aortic or major branch-vessel inflammation, pulse deficit, limb ischemia, renal-artery disease, coarctation-like aortic narrowing, aneurysm, or malperfusion in a large-vessel pattern belongs in the GCA/Takayasu reasoning described here. A distal-vessel syndrome, vasospastic presentation, isolated medium-vessel pattern, or atypical vascular distribution should not be forced into that pathway. The safer move is to define the vascular danger, protect threatened tissue, and seek disease-specific medical interpretation before assigning a label.

Buerger disease is a good example of why this boundary matters. Thromboangiitis obliterans can present with limb-threatening distal disease and may require vascular-surgery involvement, but its evidence base and clinical behavior are not direct extensions of large-vessel vasculitis guidance. Long-term cohort data in thromboangiitis obliterans support discussing it as a separate limb-risk disorder rather than as a Takayasu or GCA variant Long-Term Outcome Prognostic 2018. In this chapter, Buerger disease should therefore remain a scope boundary and referral prompt, not a place to import large-vessel imaging rules or Takayasu repair timing.

Raynaud-spectrum presentations require the same restraint. Vasospasm, connective-tissue disease, distal digital ischemia, embolic disease, atherosclerosis, and inflammatory arteriopathy can overlap at the bedside, but the LVV sources admitted here do not support a detailed Raynaud treatment pathway. The vascular surgeon’s role is to identify tissue threat, exclude surgically relevant occlusive or embolic disease when appropriate, and avoid overcalling large-vessel vasculitis when the distribution and clinical context do not fit.

The same caution applies to medium-vessel vasculitis and rare peripheral inflammatory syndromes. The vascular decision may still be urgent—intestinal ischemia, limb threat, aneurysm, hemorrhage, renal risk, or tissue loss—but the disease framework must come from disease-specific sources. Without that support, the safest statement is a boundary statement: define the vascular consequence, avoid unsupported extrapolation, and involve the medical team most familiar with the suspected inflammatory syndrome. Detailed ANCA induction or maintenance strategies, pregnancy-specific Takayasu management, and rare biologic algorithms are not part of this vascular chapter’s supported scope.

For everyday communication, the decision sentence should name three things: inflammatory state, vascular consequence, and time pressure. “Controlled inflammation with fixed claudication” supports elective planning. “Active inflammation with no threatened territory” supports medical control and reassessment. “Active or incompletely controlled disease with renal, cerebral, mesenteric, limb, ocular, aneurysmal, or rupture danger” supports urgent joint decision-making. “Uncertain inflammation with nonspecific vascular change” supports better diagnostic clarification rather than premature repair. EULAR imaging recommendations and current imaging synthesis support separating activity, damage, and follow-up purpose in this way EULAR recommendations use 2023 · LVV 2024.

This boundary protects patients from opposite errors. One error is therapeutic nihilism: assuming that every lesion will improve with medical treatment and failing to repair a dangerous fixed stenosis, aneurysm, or malperfusion syndrome. The other is procedural overreach: treating every angiographic abnormality as if revascularization will solve the inflammatory disease. Large-vessel vasculitis care is safest when the team can say which problem is being treated today, which problem is being watched, and which suspected diagnosis requires a separate disease-specific pathway.